The Retina Radar With Dr. Arshad Khanani on Gene Therapy, TKIs, Emerging Treatments, and FDA Trial Guidance
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; AbbVie Inc.; Astellas; Apellis Pharmaceuticals, Inc.; Opthea; Alimera Sciences, Inc.; EyePoint Pharmaceuticals, Inc.; Neurotech Pharmaceuticals, Inc.; REGENXBIO Inc.; and Ocular Therapeutix, Inc.
Activity Description
Retinal diseases are a leading cause of global vision impairment, driven by an increasing prevalence and the need for more effective treatment. Although clinical trials have shown promising results for various therapies, real-world application often yields less impressive outcomes due to factors like under-treatment and patient non-adherence. New and emerging therapies for retinal diseases aim to reduce the burden of frequent injections through innovative mechanisms and delivery systems. Recent advances include development of promising investigational treatments targeting gene and tyrosine kinase pathways. In this CE activity, expert faculty assess the latest data from gene therapy and tyrosine kinase inhibitor trials. They also review the FDA's latest guidance for the design of clinical trials as well as the newest data regarding advances in vitreoretinal care.
Target Audience
The intended audience for this activity is US-based ophthalmologists, retina specialists, optometrists, and other healthcare professionals involved in the management of retinal diseases.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Assess the latest data from gene therapy trials and review the efficacy and safety of various delivery approaches.
- Describe the mechanism of action of tyrosine kinase inhibitors and the latest clinical data on their use in the treatment of retinal diseases.
- Review treatments with new mechanisms of action and clinical data that supports their use in the treatment of retinal diseases.
- Review ongoing clinical trials and the latest data regarding advances in vitreoretinal care.
- Summarize the latest FDA guidance regarding clinical trial designs for neovascular age-related macular degeneration (nAMD) treatment.
Activity Chair
Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Professor of Surgery
University of Nevada, Reno School of Medicine
Reno, NV
Faculty
Dilsher S. Dhoot, MD, FASRS
Vitreoretinal Surgeon
California Retina Consultants/Retina Consultants of America
Santa Barbara, CA
Jennifer I. Lim, MD, FARVO, FASRS
Professor of Ophthalmology
Marion H. Schenk Chair and UIC Distinguished Professor of Ophthalmology
Director of the Retina Service
Vice-Chair for Diversity and Inclusion
Department of Ophthalmology
University of Illinois at Chicago College of Medicine
Chicago, IL
SriniVas R. Sadda, MD
Professor of Ophthalmology, UCLA
Doheny Eye Institute
Los Angeles, CA
Lejla Vajzovic, MD, FASRS
Director, Duke Surgical Vitreoretinal Fellowship Program
Co-Director, Duke Pediatric Retina and Optic Nerve Center
Director, Duke Eye Center Continuing Medical Education
Professor of Ophthalmology With Tenure
Adult and Pediatric Vitreoretinal Surgery and Diseases
Duke University Eye Center
Durham, NC
Glenn Yiu, MD, PhD
Professor of Ophthalmology
University of California, Davis Health
Sacramento, CA
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
ACCREDITATION
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 31, 2024, to December 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, listen to the podcasts, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 5 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Dilsher S. Dhoot, MD, FASRS
Consultant: EyePoint
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, AbbVie, Adverum, Alcon, Amgen, Annexin, Annexon, Apellis, Aviceda, Beacon Therapeutics, Clearside, Complement Therapeutics, Exegenesis, EyePoint, Frontera, Genentech, Gyroscope, i-Lumen, Iveric Bio, Janssen, Kodiak, Kriya, Nanoscope, Novartis, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Oxular, Oxurion, Perfuse, Ray Therapeutics, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Unity Bio, Vanotech
Speaker Contracted by Ineligible Company: IVERIC bio
Independent Research Contractor: 4DMT, Adverum, Alexion, Annexon, Apellis, Aviceda, EyePoint, Exegenesis, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Neurotech, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Regenxbio, Roche, Unity Bio, Vanotech
Stock Options: Aviceda, Oculis, Opthea, Perfuse, PolyPhotonix
*Individual Stocks (privately held): RevOpsis
Jennifer I. Lim, MD, FARVO, FASRS
Advisor: Alimera, Ocular Therapeutix, Regeneron, Regenxbio
Independent Research Contractor: Adverum, Aldeyra, Chengdu, Genentech, Graybug, Janssen/J&J Vision, Kyoto Drug Development, NGM, Regenxbio, Roche/Genentech
SriniVas R. Sadda, MD
No relevant financial relationships to disclose.
Lejla Vajzovic, MD, FASRS
Advisor: Astellas, Biocryst, Clearside, Ocugen, Ocular Therapeutix, Regenxbio
Consultant: AbbVie/Allergan, Alcon, Alimera, Apellis, Bausch + Lomb, BVI, Clearside, Coherus, DORC, Genentech, Guidepoint, Gyroscope, IVERIC bio, Janssen/J&J Vision, Nanoscope, Novartis, Ocugen, Ocular Therapeutix, Ocular Surgical, OcuTerra, ONL Therapeutics, Outlook Therapeutics, Regeneron, Regenxbio
Speaker Contracted by Ineligible Company: AbbVie/Allergan, Alcon, Apellis, DORC, IVERIC bio, Ocular Surgical
Independent Research Contractor: Alcon, Aldeyra, Apellis, Beacon, Genentech, Gyroscope, Janssen/J&J Vision, Novartis, Ocular Therapeutix, Regenxbio
Glenn Yiu, MD, PhD
Consultant: 4DMT, Adverum, Clearside, Ray Therapeutics, Regenxbio
*Will not discuss business lines or products of company(ies).
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. Links to text-based transcripts of these podcasts are available within.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com